It was my pleasure to meet Meysam Seyyedifar of OSVAH Pharmaceutical Company at the Singapore conference. On their behalf, I would like to announce their new version of Deferasirox, Osveral® to our group. Osveral® is the equivalent of Exjade and has gone through physicochemical tests and shows equality with Exjade. (Once a drug is introduced, generic equivalents do not have to undergo the same testing on patients as the original drug, but rather, chemical equality is shown. Patients can expect the same results once chemical equality has been proven). Osveral is an oral chelator and is taken in the same dosages as Exjade in the same manner.
This is very good news for patients in Iran and elsewhere, as it offers a new opportunity to thalassemia clinics throughout the region, as the makers of Osveral are very willing to offer their lower priced alternative to Exjade for export to other countries. Medical providers interested in learning more about providing Osveral to their patients should contact the company.
· OSVAH Pharmaceutical Company
· +982188561269
·
www.osvahpharma.com For more information see the attached file. Efficacy and safety of Osveral® (Deferasirox) in Iranian Thalassemic Patients with transfusional iron overload.